Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - MEDLINE

Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - EMBASE

Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency - Description of the Journal/Reference databases used

List of centrally authorised products requiring a notification of a change for update of annexes

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Committee for Medicinal Products for Veterinary Use (CVMP): 13-15 February 2024, European Medicines Agency, Amsterdam, the Netherlands, from 13 February 2024 to 15 February 2024

Human medicines European public assessment report (EPAR): Exblifep, cefepime,enmetazobactam, Date of authorisation: 21/03/2024, Status: Authorised

EMA Management Board: highlights of March 2024 meeting

EMEA-000524-PIP01-08

Stakeholder engagement highlights 2022